It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
PPM1D/Wip1 is a negative regulator of the tumor suppressor p53 and is overexpressed in several human solid tumors. Recent reports associate gain-of-function mutations of PPM1D in immune cells with worse outcomes for several human cancers. Here we show that mice with genetic knockout of Ppm1d or with conditional knockout of Ppm1d in the hematopoietic system, in myeloid cells, or in neutrophils all display significantly reduced growth of syngeneic melanoma or lung carcinoma tumors. Ppm1d knockout neutrophils infiltrate tumors extensively. Chemical inhibition of Wip1 in human or mouse neutrophils increases anti-tumor phenotypes, p53-dependent expression of co-stimulatory ligands, and proliferation of co-cultured cytotoxic T cells. These results suggest that inhibition of Wip1 in neutrophils enhances immune anti-tumor responses.
Wip1 is a negative regulator of the tumor suppressor p53 and is overexpressed in several human cancers. Here the authors show that inactivation of Wip1 in neutrophils promotes p53-dependent expression of co-stimulatory ligands and anti-tumor immune responses, reducing tumor growth in preclinical cancer models.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Grigorash, Bogdan B 4
; Petukhov, Alexey V 5 ; Singhal Sunil 6 ; Eruslanov Evgeniy 6
; Chaloyard Jeanne 1
; Lagorgette Lisa 1
; Hadi Tarik 1 ; Baidyuk, Ekaterina V 7 ; Sakai Hiroyasu 3
; Tessarollo Lino 8 ; Ryffel Bernhard 9 ; Mazur, Sharlyn J 3 ; Lirussi Frederic 10
; Garrido, Carmen 11 ; Appella Ettore 3 ; Demidov, Oleg N 12
1 University of Burgundy Franche-Comté, INSERM UMR1231, LipSTIC, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313)
2 University of Burgundy Franche-Comté, INSERM UMR1231, LipSTIC, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313); Institute of Cytology, RAS, St. Petersburg, Russia (GRID:grid.418947.7) (ISNI:0000 0000 9629 3848)
3 Center for Center Research, National Cancer Institute, Laboratory of Cell Biology, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
4 Institute of Cytology, RAS, St. Petersburg, Russia (GRID:grid.418947.7) (ISNI:0000 0000 9629 3848); NTU Sirius, Sochi, Russia (GRID:grid.418947.7)
5 NTU Sirius, Sochi, Russia (GRID:grid.418947.7); Almazov National Medical Research Centre, St. Petersburg, Russia (GRID:grid.452417.1)
6 University of Pennsylvania, Department of Surgery, Perelman School of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
7 Institute of Cytology, RAS, St. Petersburg, Russia (GRID:grid.418947.7) (ISNI:0000 0000 9629 3848)
8 Center for Cancer Research, National Cancer Institute, Mouse Cancer Genetics Program, Frederick, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129)
9 University of Orléans, CNRS, UMRP735, INEM, Experimental and Molecular Immunology and Neurogenetics, Orléans, France (GRID:grid.112485.b) (ISNI:0000 0001 0217 6921)
10 University of Burgundy Franche-Comté, INSERM UMR1231, LipSTIC, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313); University hospital of Besançon (CHU), 2 Boulevard Fleming, PACE, Plateau d’Analyses Chromatographiques et Elémentaires, Department of Pharmacology-Toxicology & Metabolomics, BESANCON, France (GRID:grid.411158.8) (ISNI:0000 0004 0638 9213)
11 University of Burgundy Franche-Comté, INSERM UMR1231, LipSTIC, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313); Georges François Leclerc Center, Dijon, France (GRID:grid.5613.1)
12 University of Burgundy Franche-Comté, INSERM UMR1231, LipSTIC, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313); Institute of Cytology, RAS, St. Petersburg, Russia (GRID:grid.418947.7) (ISNI:0000 0000 9629 3848); NTU Sirius, Sochi, Russia (GRID:grid.418947.7)




